Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;29(10):1219-1227.
doi: 10.1002/pds.5117. Epub 2020 Sep 14.

Assessing the impact of unmeasured confounders for credible and reliable real-world evidence

Affiliations
Review

Assessing the impact of unmeasured confounders for credible and reliable real-world evidence

Xiang Zhang et al. Pharmacoepidemiol Drug Saf. 2020 Oct.

Abstract

Purpose: We review statistical methods for assessing the possible impact of bias due to unmeasured confounding in real world data analysis and provide detailed recommendations for choosing among the methods.

Methods: By updating an earlier systematic review, we summarize modern statistical best practices for evaluating and correcting for potential bias due to unmeasured confounding in estimating causal treatment effect from non-interventional studies.

Results: We suggest a hierarchical structure for assessing unmeasured confounding. First, for initial sensitivity analyses, we strongly recommend applying a recently developed method, the E-value, that is straightforward to apply and does not require prior knowledge or assumptions about the unmeasured confounder(s). When some such knowledge is available, the E-value could be supplemented by the rule-out or array method at this step. If these initial analyses suggest results may not be robust to unmeasured confounding, subsequent analyses could be conducted using more specialized statistical methods, which we categorize based on whether they require access to external data on the suspected unmeasured confounder(s), internal data, or no data. Other factors for choosing the subsequent sensitivity analysis methods are also introduced and discussed, including the types of unmeasured confounders and whether the subsequent sensitivity analysis is intended to provide a corrected causal treatment effect.

Conclusion: Various analytical methods have been proposed to address unmeasured confounding, but little research has discussed a structured approach to select appropriate methods in practice. In providing practical suggestions for choosing appropriate initial and, potentially, more specialized subsequent sensitivity analyses, we hope to facilitate the widespread reporting of such sensitivity analyses in non-interventional studies. The suggested approach also has the potential to inform pre-specification of sensitivity analyses before executing the analysis, and therefore increase the transparency and limit selective study reporting.

Keywords: causal inference; pharmacoepidemiology; practical recommendation; real world evidence; sensitivity analyses; unmeasured confounding.

PubMed Disclaimer

Similar articles

Cited by

References

REFERENCES

    1. Attempt to replicate clinical trials with real-world data generates real-world criticism, too STAT News. July 3, 2019. Available from https://www.statnews.com/2019/07/03/replicate-clinical-trials-real-world...
    1. How real world evidence was used to support approval of Ibrance for male breast cancer. The Cancer Letter. April 19, 2019. Available from https://cancerletter.com/articles/20190419_2/
    1. European Medicines Agency. Guidance for companies considering the adaptive pathways approach. 2016. Available from https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/g.... Accessed December 1, 2019.
    1. U.S. Food and Drug Administration. Framework for FDA's Real-World Evidence Dent Program 2018. https://www.fda.gov/media/120060/download. Accessed December 1, 2019.
    1. Wedam S, Fashoyin-Aje L, Bloomquist E, et al. FDA approval summary: Palbociclib for male patients with metastatic breast cancer. Clin Cancer Res. 2019;26(5):1208-1212.

LinkOut - more resources